2025-12-19 - Analysis Report
Okay, here's a report on Natera Inc. (NTRA), based on the provided information:

**1. Return Rate Comparison**

*   **Company Overview:** Natera Inc. is a genetic testing company focused on women's health, oncology, and organ health.
*   **NTRA Cumulative Return:** 130.27%
*   **VOO (S&P 500) Cumulative Return:** 99.35%
*   **Divergence:**
    *   Current: 36.2
    *   Relative Divergence: 47.4
*   **Analysis:** NTRA has significantly outperformed the S&P 500 over the period examined, with a difference of 30.92%. The "Divergence" figure suggests that the current outperformance is near the middle of its historical range relative to the S&P 500.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD  | Alpha   | Beta   | Cap(B) |
|------------|---------|------|---------|--------|--------|
| 2015-2017  | -10.0%  | 70.1% | -34.0%  | -0.2   | 1.2    |
| 2016-2018  | 22.0%   | 80.0% | 6.0%    | 0.1    | 1.9    |
| 2017-2019  | 50.0%   | 80.0% | 28.0%   | 1.0    | 4.7    |
| 2018-2020  | 186.0%  | 80.5% | 163.0%  | 1.1    | 13.9   |
| 2019-2021  | 96.0%   | 80.5% | 49.0%   | 1.6    | 13.0   |
| 2020-2022  | -77.0%  | 80.5% | -76.0%  | 0.1    | 5.6    |
| 2021-2023  | -194.0% | 76.6% | -195.0% | -1.1   | 8.7    |
| 2022-2024  | 8.0%    | 76.6% | -13.0%  | -1.2   | 22.1   |
| 2023-2025  | 157.0%  | 76.6% | 94.0%   | 0.1    | 31.3   |

*   **CAGR:** Fluctuates significantly, indicating periods of high growth and significant decline.
*   **MDD:** High Maximum Drawdown values suggest the stock is volatile and prone to substantial losses from peak to trough.
*   **Alpha:** Alpha varies widely, indicating periods where NTRA significantly outperformed (positive alpha) or underperformed (negative alpha) its expected return based on its beta. The stock has recently shown better performance against the market.
*   **Beta:** Beta fluctuates around 1, suggesting the stock's volatility is generally similar to the market. However, there are periods where beta is significantly higher or lower, indicating increased or decreased sensitivity to market movements.
*   **Cap(B):** Market capitalization has generally increased over time, but the volatility of the price changes has affected market cap significantly.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** $224.74
*   **Previous Close:** $225.49
*   **Change:** -$0.33
*   **5-day SMA:** 227.60
*   **20-day SMA:** 234.18
*   **60-day SMA:** 202.36

*   **Analysis:** The current price is below both the 5-day and 20-day SMAs, suggesting a short-term downward trend. The 60-day SMA is significantly lower than the 5-day and 20-day SMAs, implying that while there may be a recent dip, the longer-term trend has been upward.

**3. Indicators Analysis**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 27.42 (Oversold)
*   **PPO:** -1.48
*   **Hybrid Signal:** Buy 100% of cash (4 shares), suggesting a very safe investment. Monthly invest 0.8% of total investment ($1,000.00). Cash Ratio: 0% on 2025-12-01
*   **Recent (20 days) relative divergence change:** -2.4 (Negative Trend)
*   **Expected Return (%):** -50.6% (Long-term underperformance)

*   **Analysis:**
    *   The MRI indicates a medium level of investment risk.
    *   The RSI suggests the stock is currently oversold, potentially signaling a buying opportunity.
    *   The PPO indicates a relative change in price and the value is trending downwards.
    *   The Hybrid Signal suggests a buy signal, considering it to be very safe.
    *   The negative change in relative divergence over the past 20 days suggests a short-term downward trend.
    *   The Expected Return is very negative, suggesting a long-term underperformance of the stock, relative to the market.

**4. Recent News & Significant Events**

*   **Positive Sentiment:**
    *   Analyst target price increase by Barclays.
    *   Analysts are bullish on Natera (NTRA), and named it as a top healthcare stock.
*   **Mixed/Neutral Sentiment:**
    *   Article discussing a successful investor who is buying the stock.
    *   Blood test helps spot colon cancer patients who gain from celecoxib
    *   Seeking Alpha article suggesting a "Hold" rating despite growth.
*   **Negative Sentiment:**
    *   Thrivent Financial for Lutherans Cuts Stake in Natera, Inc.

*   **Analysis:** Recent news presents a mixed picture. Analyst upgrades and bullish sentiment provide positive signals, while a stake reduction by an institutional investor could raise concerns.

**4-2) Analyst Opinions**

*   **Consensus:** Strong Buy (1.47 on a 1-5 scale)
*   **Opinions:** 19 analysts
*   **Target Price:**
    *   Average: $244.42
    *   High: $280.00
    *   Low: $186.00

*   **Analysis:** The strong buy consensus and positive target prices suggest analysts are generally optimistic about the stock's future performance.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-11-07 | -0.64 | 0.59 B$    |
| 2025-08-08 | -0.74 | 0.55 B$    |
| 2025-05-09 | -0.5  | 0.50 B$    |
| 2024-11-12 | -0.26 | 0.44 B$    |
| 2025-11-07 | -0.26 | 0.44 B$    |

*   **Analysis:** EPS (Earnings Per Share) remains negative, indicating the company is not yet profitable. However, revenue is generally increasing, suggesting growth in the business.

**6. Financial Information**

**Revenue and Profitability**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.59B    | 64.91%        |
| 2025-06-30   | $0.55B    | 63.41%        |
| 2025-03-31   | $0.50B    | 63.12%        |
| 2024-12-31   | $0.48B    | 62.94%        |
| 2024-09-30   | $0.44B    | 61.79%        |

*   **Analysis:** Revenue is consistently growing, and profit margins are relatively stable and high, suggesting the company has strong pricing power.

**Capital and Profitability**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-09-30   | $1.25B    | -6.99%    |
| 2025-06-30   | $1.25B    | -8.10%    |
| 2025-03-31   | $1.24B    | -5.40%    |
| 2024-12-31   | $1.20B    | -4.50%    |
| 2024-09-30   | $0.88B    | -3.60%    |

*   **Analysis:** Equity is increasing, indicating a strengthening financial position. However, ROE (Return on Equity) is negative, reflecting the company's current lack of profitability.

**7. Comprehensive Analysis**

*   **Overall:** Natera Inc. presents a mixed picture for investors.
*   **Strengths:** Strong revenue growth, high profit margins, positive analyst sentiment, and potential for future growth in genetic testing.
*   **Weaknesses:** Consistent unprofitability, high volatility (MDD), negative expected return compared to S&P 500, and mixed news sentiment. The recent 20 days relative divergence change implies short-term negative volatility, and the hybrid signal shows a buy opportunity.
*   **Recommendation:** Given the high volatility and unprofitability, NTRA is a higher-risk investment. It is advisable to approach the stock cautiously and monitor its performance closely. Given the long term expected underperformance, it is a risky investment in the long term. If the investor is looking to make short-term profits, the RSI and hybrid signals imply that there is a good oppertunity to buy the stock.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.